McNeil compliance with NAD
This article was originally published in The Tan Sheet
Executive Summary
Ad watchdog "considered it incredibly unfortunate" that a St. Joseph aspirin TV commercial "continued to air without modification for months after" NAD deemed the ad misleading, according to recent Case Reports. In February, CBBB division concluded McNeil should modify ad claims for St. Joseph to avoid inaccurately communicating 81 mg is the appropriate, recommended dosage for aspirin therapy (1"The Tan Sheet" March 25, 2002, p. 6). In response to NAD compliance proceeding, McNeil said original ad aired through May while revisions were planned and instituted. The case, brought by Bayer, has since moved to federal court (2"The Tan Sheet" April 29, 2002, p. 14)...
You may also be interested in...
Bayer, McNeil St. Joseph Aspirin Ad Dispute Moves To Federal Court
A recent British Medical Journal study does not support McNeil Consumer & Specialty Pharmaceuticals' advertising claims that 81 mg aspirin "is just as effective as 325 mg in reducing the risk of recurrent heart attacks," Bayer says in a lawsuit filed in New York federal court April 25
McNeil St. Joseph “Aspirin Therapy” Claim Needs Refining, NAD Says
McNeil Consumer & Specialty Pharmaceuticals should more narrowly target future advertising claims for St. Joseph Adult Low-Strength Aspirin "to avoid the risk of inaccurately communicating that 81 mg is the appropriate and recommended dosage for all types of 'aspirin therapy,'" the National Advertising Division says
Investors Go Beserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.